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Summary 
Background: Until now, a proper biomarker(s) to evaluate
sarcoidosis activity has not been recognized. The aims of
this study were to evaluate the sensitivity and specificity of
the two biomarkers of sarcoidosis activity already in use
(serum angiotensin converting enzyme – ACE and serum
chito triosidase) in a population of 430 sarcoidosis patients.
The activities of these markers were also analyzed in a
group of 264 healthy controls. 
Methods: Four hundred and thirty biopsy positive sarcoido-
sis patients were divided into groups with active and inactive
disease, and groups with acute or chronic disease. In a sub-
group of 55 sarcoidosis patients, activity was also assessed
by F-18 fluorodeoxyglucose positron emission tomography
(18F-FDG-PET) scanning. Both serum chitotriosidase and
ACE levels showed non-normal distribution, so nonparamet-
ric tests were used in statistical analysis. 
Results: Serum chitotriosidase activities were almost 6
times higher in patients with active sarcoidosis than in
healthy controls and inactive disease. A serum chitotrio -
sidase value of 100 nmol/mL/h had the sensitivity of
Kratak sadr`aj
Uvod: Do sada, nisu na|eni odgovaraju}i biomarkeri za
procenu aktivnosti sarkoidoze. Ciljevi studije su bili: pro ce -
na osetljivosti i specifi~nosti dva ve} kori{}ena bio mar kera
aktivnosti sarkoidoze (serumskog angiotenzin-konvertu ju -
}eg enzima (ACE) i serumske hito triozidaze) u populaciji od
430 bolesnika sa sarkoidozom. Ovi markeri su tako|e ana -
lizirani u kontrolnoj grupi od 264 zdrava ispitanika.
Metode: ^etiristo trideset bolesnika sa sarkoidozom koja je
dokazana biopsijom podeljeno je u grupe sa aktivnom i ne -
aktivnom bole{}u i u grupe sa akutnom i hroni~nom sarko -
idozom. U podgrupi od 55 bolesnika, aktivnost sarko ido ze
je pro ce nji vana i F18 fluorodeoksiglukoznom pozi tron skom
emisionom tomografijom (18F-FDG-PET). Nivoi serumske
hitotriozi daze i ACE nisu pratili normalnu distribuciju, tako
da su u statisti~koj analizi kori{}eni neparametrijski testovi.
Rezultati: Nivoi serumske hitotriozidaze su skoro 6 puta bili
vi{i kod bolesnika sa aktivnom sarkoidozom u odnosu na
kontrolnu grupu i na bolesnike sa neaktivnom bole{}u.
Nivo serumske hitotriozidaze od 100 nmol/mL/h pokazao
je osetljivost od 82,5% i specifi~nost od 70,0%. Cut off
J Med Biochem 2016; 35 (4) 391
Introduction
Sarcoidosis is a multisystem granulomatous dis-
ease of unknown etiology and unpredictable course
(1). The unpredictable clinical course of sarcoidosis
has encouraged the research of biomarkers useful for
predicting disease activity and the outcome. Severity
of sarcoidosis is routinely evaluated by a staging sys-
tem based on the appearance of the chest X ray, sup-
ported by pulmonary function tests and evaluation of
extrapulmonary disease (2). Significant efforts have
been made for decades in order to identify biochem-
ical parameters that can support the evaluation of dis-
ease activity (3–4).
Until recently, the increase in angiotensin-con-
verting enzyme (ACE) has been the most frequently
used laboratory test in sarcoidosis. The enzyme is also
supposed to give indication of total body granuloma
burden (7–8). However, the value of elevated serum
ACE in sarcoidosis is still a matter of debate.
Determination of serum ACE has an estimated sensi-
tivity of only 57% (9). Especially in the first months of
acute disease, ACE levels may be within the normal
range. Despite the fact that the ACE is the most fre-
quently used marker of sarcoidosis activity, the diag-
nostic and prognostic usefulness of the serum ACE
remains uncertain. In a study of 1941 patients with
sarcoidosis, 1575 healthy control subjects, and 1355
patients with other diseases, the sensitivity of elevated
serum ACE for the diagnosis of sarcoidosis was 57%,
the specificity 90%, positive predictive value 90%, but
negative predictive value only 60% (10). 
Polymorphisms of the ACE gene may lead to
changes in the serum ACE level in both normal con-
trol subjects and patients with sarcoidosis. The poly-
morphism with insertion (I) or deletion (D) of a por-
tion of the gene affects the enzyme activity, so that
the subjects with DD have higher serum ACE levels
than those with II polymorphism (11–12). Given the
fact that I/D allele frequencies can differ greatly
between ethnicities, genotype corrected reference
values for ACE should be established locally (13).
The correlation between serum ACE levels and
sarcoidosis activity or even response to treatment
seems to be relatively poor (14). These limitations of
serum ACE as the disease marker have stimulated an
ongoing search for better ones. Regarding the crucial
role of chronically activated macrophages in the
pathogenesis of sarcoidosis, chitotriosidase – a new
potential marker of the disease was introduced for the
first time in 2004 by Grosso et al. (15). 
The enzyme chitotriosidase is originally involved
in the degradation of chitin; however, the enzyme is
also functional in humans (15–16), although its exact
physiological function in humans still remains uncer-
tain (17–18). It has been already evaluated that in
pathological conditions, chitotriosidase is considered
a serum marker of macrophage activation. In these
cases pathological tissue macrophages produce an
additional amount of chitotriosidase as observed in a
number of lysosomal storage diseases i.e. Gaucher
syndrome (4–6).
The lack of reliable parameters for monitoring
sarcoidosis activity led to a hypothesis that serum chi-
totriosidase may be a dependable parameter in iden-
tifying patients with active disease (4, 15–18). The
idea of detecting serum chitotriosidase in patients
with sarcoidosis originated from the evidence of direct
involvement of activated macrophages in the patho-
genesis of sarcoidosis and granulomatous in flam -
mation (15–18).
A group of authors from Siena University has
noticed a significantly higher activity of chitotriosidase
in the serum of patients with sarcoidosis compared
with controls; higher activity of serum chitotriosidase
was also reported to be more elevated in active sar-
coidosis than in patients with inactive disease.
Significant correlations with the radiographic stages
of lung sarcoidosis, radiological CT features, BAL
cells characteristics, suggested that the enzyme could
be a marker of disease severity (15–16).
The first objective of this study was to evaluate
the utility of serum chitotriosidase in assessment of
82.5% and specificity of 70.0%. A serum ACE activity cut-
off value of 32.0 U/L had the sensitivity of 66.0% and the
specificity of 54%. A statistically significant correlation was
obtained between the focal granulomatous activity detect-
ed on 18F-FDG PET/CT and serum chitotriosidase levels,
but no such correlation was found with ACE. The levels of
serum chitotriosidase activity significantly correlated with
the disease duration (P<0.0001). Also, serum chitotriosi-
dase significantly correlated with clinical outcome status
(COS) categories (r=0.272, P=0.001).
Conclusions: Serum chitotriosidase proved to be a reliable
biomarker of sarcoidosis activity and disease chronicity.
Keywords: sarcoidosis, serum chitotriosidase, serum
angio tensin converting enzyme, biomarker
vrednost od 32,0 U/L za aktivnost ACE u serumu pokazala
je osetljivost od 66,0% i specifi~nost od samo 54,0%.
Statisti~ki zna~ajna povezanost je na|ena izme|u fokalne
granulomatozne aktivnosti koja je detektovana pomo}u
18F-FDG PET/CT i nivoa serumske hitotriozidaze, dok takva
kore lacija nije na|ena sa ACE. Nivoi serumske hitotrio zi -
daze su bili u zna~ajnoj korelaciji sa trajanjem bolesti
(P<0,0001). Serumska hitotriozidaza je bila zna~ajno po -
vezana sa ka te gorijama klini~kog ishoda (COS) (r=0,272,
P=0,001).
Zaklju~ak: Aktivnost hitotriozidaze u serumu je dokazano
pouzdan biomarker za procenu aktivnosti i hroniciteta sar -
koi doze.
Klju~ne re~i: sarkoidoza, hitotriozidaza, angiotenzin kon -
ver tuju}i enzim, biomarker
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sarcoidosis activity and to correlate it with other mark-
ers of disease activity i.e. chest X ray, number of or -
gans involved, disease duration and for the first time,
F-18 fluorodeoxyglucose positron emission tomo -
graphy (18F-FDG PET/CT) scan findings. The second
objective of this study was to correlate serum chito -
triosidase levels in the largest until now cohort of sar-
coidosis patients with the serum ACE levels, in order
to assess which marker the clinicians can rely on bet-
ter when determining sarcoidosis activity.
Material and Methods
Study design
In a large cohort of 430 biopsy positive sarco -
idosis patients, the associations between serum chito -
triosidase activity and ACE serum levels were tested in
correlation with radiographic stage of sarcoidosis,
number of organs involved and disease duration. It is
conceivable that the extent of involvement and quan-
tification of sarcoidosis activity can be accurately
assessed by F-18 fluorodeoxyglucose positron emis sion
tomography (18F-FDG-PET) scanning (19–21), so we
also correlated serum chitotriosidase levels in a sub-
group of 55 sarcoidosis patients, with the disease activ-
ity resulting from PET scanning examination.
All patients included in this study were diag-
nosed in the Clinic of Pulmonary Diseases, Clinical
Center of Serbia, Belgrade, Serbia. The examined
population included 299 females and 131 males, 23
to 77 years old. Healthy control group consisted of
264 subjects matched for age and gender with
patients’ group. This study was approved by the insti-
tution’s ethics committee and all patients consented
to participate.
Definition of activity
Activity of sarcoidosis was defined by the pres-
ence of clinical symptoms such as cough, dyspnea,
chest pain or tightness of the chest, fever, bone or
joint pains and fatigue, together with or without
pathologic chest X ray findings. Activity was also sug-
gested in clinically asymptomatic patients, but with
absolute and marked roentgenographic worsening.
Additionally, patients with major manifestations such
as recently developed skin lesions, parotid or ocular
involvement, peripheral lymphadenopathy, or deterio-
ration of pulmonary function tests, were considered
to have active disease. Inactive sarcoidosis was sug-
gested in cases with absent clinical symptoms togeth-
er with a negative or nonprogressive chest X-ray. 
According to these criteria, at the time of the
study, 230 patients were considered to have active
sarcoidosis, while 200 patients had inactive sarcoido-
sis. Patients complained of more than one symptom,
including cough 18% (41/230), chest pain or tight-
ness of the chest 35% (80/230), fever 12% (27/230),
bone pain 33% (76/230), joint pain or stuffiness 22%
(51/230), and fatigue 33% (76/230).
Disease duration
Regarding disease duration, patients were also
divided into a group of acute sarcoidosis (147
patients) and a group of chronic sarcoidosis (283
patients). The mean duration of sarcoidosis was
5.69±6.79 years, ranging from 6 months to 33
years. Acute sarcoidosis was defined as disease that
persisted for less than two years. Frequently, acute
sarcoidosis had an abrupt onset with symptoms
including erythema nodosum, polyarthralgia, bilateral
hilaradenopathy and occasionally diffuse parenchyma
infiltration, but the disease usually remitted sponta-
neously (22). In contrast, chronic sarcoidosis was
defined as disease with both symptoms and signs of
sarcoidosis activity and parameters of the activity
(measuring serum ACE and hypercalciuria) unremit-
ting for more than two years. Unfortunately for these
patients, therapy tends to only relieve symptoms and
rarely leads to resolution of structural abnormalities
(22). 
The World Association of Sarcoidosis and Other
Granulomatous disease (WASOG) established a task
force to provide a better definition of clinical outcome
in sarcoidosis (COS) which takes into account the
variable patterns of outcome with/without therapy.
The clinical outcome of patients was examined five
years after diagnosis of sarcoidosis was established
(23). The number of patients with an adequate fol-
low-up (at least 5 years) was 159. They were classi-
fied in subgroups according to clinical outcome status
– COS (23). The classification ranges from COS-
1Ø(0/159) – patients in complete remission, not
requiring therapy in the last year and never treated,
and those not requiring therapy in the last year but
previously treated – COS-2 (7/159); to those with
minor involvement, defined as less than 25% of lung
involvement at chest x-ray, not needing therapy in the
last year, who were also classified into COS-3 (0/159)
– never treated, and COS-4 (26/159) – not treated in
the last year. Patients with persistent disease not on
systemic therapy were divided into COS-5 (0/159) –
never treated, and COS-6 (19/159) – not treated in
the last year. Patients with persistent disease treated
systemically were classified into COS-7 (58/159) –
asymptomatic patients without clinical functional de -
terioration in the last year, COS-8 (14/159) – symp-
tomatic patients without clinical functional deteriora-
tion in the last year, and COS-9 (35/159) – patients
with clinical functional deterioration in the last year.
In order to clarify the extent of organ involve-
ment and quantification of sarcoidosis, a subgroup of
55 patients underwent 18F-FDG PET/CT examination
on 64 slice hybrid PET/CT scanner (Siemens Bio -
graph, Siemens Medical Solutions USA Inc., Hoffman
Estates, Illinois, USA). Patients were chosen accord-
ing to following criteria: chronicity, radiographic pro -
gression and multiorgan involvement. Findings of
18F-FDG PET/CT were scored as positive or negative
for inflammation. The findings were considered posi-
tive in case of increased 18F-FDG uptake above blood
vessels in the mediastinum and/or lung parenchyma,
or in extrathoracic sites, including lymph nodes, vis-
ceral organs (like parotid, liver, spleen), nasopharynx,
skin, muscle, or bone (20). Quantitative analysis of
18F-FDG uptake in the lesion was based on maximum
standardized uptake value (SUVmax) per focus. The
SUVmax was calculated as the activity concentration
measured at the end of the scan and corrected for
individual body weight and dose injected, as follows:
SUVmax = Tissue Activity (counts/pixel/second) ×
Ca libration Factor / Injected 18F-FDG Dose (MBq/
kilo gram body weight) (21).
Serum ACE and serum chitotriosidase 
measurements
Blood samples for chitotriosidase and ACE serum
levels were obtained from all patients. Patients includ-
ed into this study were not taking medications that
interfere with the renin–angiotensin–aldo sterone sys-
tem i.e. ACE inhibitors or angiotensin II receptor antag-
onists. Chitotriosidase activity in serum was determined
using the developed and validated method with fluoro-
genic substrate 4-methyl-um bel liferyl-b-D-N-N’-N”-
triacetylchitotrioside (Sigma Chem ical Co, St. Louis,
MO) in Mcllvaine’s citrate-phosphate buffer, pH 5.2, at
37 °C (24). Fluorescence was measured on an SPF-
500™C spectrofluorometer (SLM Instru ments, Inc.).
ACE activity was measured by the spectrophotometric
method adapted in the laboratory utilizing synthetic
tripeptide substrate N-[3-(2-furyl) acryloyl]-L phenyl -
alanylglycylglycine, using a commercial test kit (Trinity
Biotech, St. Louis, USA), on an Olympus AU 2700
automated analyzer (Beckman Coulter Bio medical
Ltd.).
Patients
All patients had pulmonary sarcoidosis and 120
(28%) had extrapulmonary sarcoidosis, with different
organs involvement. Chest X ray classification was
done using Scadding’s modified staging system:
stage 0 – no adenopathy or infiltrates; stage 1 – hilar
and mediastinal adenopathy alone; stage 2 – adeno -
pathy and pulmonary infiltrates; stage 3 – pulmonary
infiltrates alone; and stage 4 – pulmonary fibrosis
(25). Using the ACCESS organ index, we assessed the
extent of the current sarcoidosis organ involvement
(26–27). The diagnosis of sarcoidosis in any organ
system was defined as definite, probable or possible.
In this study, positive organ involvement included def-
inite or probable criteria from the ACCESS study index
(26–27). Regarding the treatment, at the time of the
study, no treatment was required in 154/430 patients
(36%), while others were treated regarding the
stage of the lung disease, different organs involve-
ment, symptoms and pulmonary function tests. Here,
a group of patients with chronic sarcoidosis (46) was
included. These were patients without significant
symptoms suggesting sarcoidosis activity but treated
with morbostatic doses of immunosuppressive thera-
py in order to prevent further deterioration of the
chronic persistent disease.
Statistical methods 
Since both serum chitotriosidase and ACE levels
were not normally distributed (as revealed by
Kolmogorov Smirnov and Shapiro-Wilk tests of nor-
mality), the nonparametric tests were used in statisti-
cal analysis (Kruskal-Wallis test and Spearman’s cor-
relation), and results were presented as median
values with interquartile ranges (IQR). Statistical
analysis was performed using SPSS v 15.0 software
(IBM, Chicago, Illinois, USA). ROC analysis and
graphic representations of data were conducted using
GraphPad Prism Version 4.0 software for Windows
(GraphPad Software, San Diego, California, USA).
Results
Clinical characteristics of study participants are
summarized in Table I. Table II represents serum ACE
and chitotriosidase levels in healthy controls and
patients with different forms of sarcoidosis. Both
serum markers, ACE and chitotriosidase levels,
showed no correlation with the age series of the ana-
lyzed population. Significantly higher were both
serum levels of chitotriosidase and ACE in male
patients (Table I).
The median value of serum ACE in healthy con-
trols was 28 U/L. Using Kruskal-Wallis test and
Conover post hoc test, statistically significant differ-
ence was found between healthy controls and sar-
coidosis patients with both acute and chronic disease.
However, statistically significant difference was found
only between healthy controls and active disease,
while the difference was not significant between
healthy controls and patients with inactive disease.
Also, serum ACE levels were significantly different
between patients with active and inactive sarcoidosis,
but the difference was not significant between acute
and chronic sarcoidosis patients (Figure 1).
The median value of serum chitotriosidase in
healthy controls was 60.0 nmol/mL/h. Kruskal-Wallis
test and Conover post hoc test showed statistically sig-
nificant difference between chitotriosidase levels in
healthy controls and patients with both acute and
chronic disease, but again the difference was not sig-
nificant between acute and chronic course of sar-
J Med Biochem 2016; 35 (4) 393
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Table I Clinical characteristics of patients.
Serum ACE levels (U/L) Serum chitotriosidase levels (nmol/mL/h)
Clinical characteristics of
patients N Median
Interquartile
range P* Median
Interquartile
range P*
Gender
Female 297 35 20–51
0.0094
116.1 51.3–235.6
0.0811
Male 132 40 28–59 139.2 73.9–259.2
Activity
Active 230 43 26–62
<0.0001
224.2 139.2–394.9
<0.0001
Inactive 199 30 20–44 56.4 27.3–111.8
Clinical course of sarcoidosis
Acute 146 39 20–56
0.1534
141.3 54–259.9
0.2996
Chronic 283 36 20–51 115.4 51.3–236.9
Stage of the lung disease
Stage 0 28 38 24–46
0.7326
51.2 21.6–92.7
0.0001
Stage 1 204 36 22–54 129.61 52.6–245.1
Stage 2 c 187 39 21–56 137.71 54.8–256.8
Stage 3 10 47 23–54 175.81 91.8–211
Organ involvement
Pulmonary 309 38 23–54
0.4925
129.6 53.7–249.9
0.1445
Extrapulmonary 120 37 19–51 105.3 51.3–228.4
Number of organs involved
1 308 38 23–54
0.8560
129.6 52.6–247.9
0.05667
2 87 39 20–52 119.9 51–234.4
3 30 38 19–50 83.2 51.3–218.7
4 4 28 16–46 56.7 56.7 (29.7–387.4)
*Kruskal-Wallis test, significant difference between subgroups P<0.05
1Significantly different from stage 0 by Conover post hoc test, P<0.01
Activity of sarcoidosis Healthy controls Inactive Active P*
ACE, U/L
Chitotriosidase, nmol/mL/h
28 (13–36)
60 (35–83)
30 (20–44)
56.4 (27.3–111.8)
43 (26–62)1,2
224.2 (139.2–394.9)1,2
0<0.0001
0.0078
Clinical course of sarcoidosis Healthy controls Chronic Acute P*
ACE, U/L
Chitotriosidase, nmol/mL/h
28 (13–36)
60 (35–83)
36 (20–51)1
115.4 (51.3–236.9)1
39 (25–56)1
141.3 (54.0–259.9)1
<0.0001
<0.0001
Results are expressed as median (interquartile range).
*Kruskal-Wallis test, significant difference between subgroups P<0.05
1Significantly different from healthy controls by Conover post hoc test, P<0.01
2Significantly different from inactive sarcoidosis by Conover post hoc test, P<0.01
Table II Serum ACE and chitotriosidase levels in healthy controls and patients with different forms of sarcoidosis.
coidosis. On the other hand, besides the statistically
significant difference between healthy controls and
patients with active and inactive disease, the differ-
ence in serum chitotriosidase level was statistically
significant between active and inactive sarcoidosis
patients (Figure 2).
Important difference was noticed between the
two potential serum markers (ACE and chitotrio -
sidase) considering sarcoidosis acivity. Investigating
the area under the receiver operating characteristic
(ROC) curve (AUC) as a performance measure of the
potential strength of the analyzed parameters to pre-
J Med Biochem 2016; 35 (4) 395
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Figure 1 Box-plots graphs: A) Serum chitotriosidase in active sarcoidosis, inactive disease and healthy controls. 
B) Serum ACE values in healthy controls, patients with active and inactive disease.
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Figure 2 Box-plots graphs: A) Serum chitotriosidase in acute versus chronic sarcoidosis and healthy controls. 
B) Serum ACE in healthy controls and sarcoidosis patients with acute and chronic disease.
dict sarcoidosis activity, for chitotriosidase the AUC
was 0.870, and for serum ACE it was only 0.643
(Figure 3). A serum chitotriosidase level of 100
nmol/mL/h had 82.5% sensitivity (to confirm active
sarcoidosis) and 70% specificity (to exclude active
sarcoidosis). Serum ACE cut off value of 32 U/L had
the sensitivity of 66% and specificity of 54%. The dif-
ference between serum chitotriosidase levels in the
different radiographic stages of lung disease was sta-
tistically significant, unlike the ACE levels (Figure 4).
However, Conover post hoc test revealed that the dif-
ference was significant only between stage 0 and later
stages of lung sarcoidosis, but not between stages 1,
2 and 3 (Table 1). In total, 159 patients were pheno-
typed in COS catego ries. Serum chitotriosidase levels
significantly corre lated with COS categories (r=0.272,
P=0.001). However, the correlation between COS
categories and serum ACE levels was not significant
(r=0.132, P=0.097).
Analyzing patients with pulmonary and extrapul-
monary sarcoidosis, neither serum chitotriosidase nor
serum ACE levels were statistically significantly dif -
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Figure 3 ROC curve: serum chitotriosidase and serum ACE
levels.
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Figure 4 Box-plots graphs. The correlation of serum chitotriosidase level with the radiographic stage of lung sarcoidosis.
Figure 5 Serum chitotriosidase levels and sarcoidosis activi-
ty assumed on 18F-FDG PET/CT.
ferent between these two groups of patients. Also,
neither serum chitotriosidase nor serum ACE levels
revealed statistically significant difference between
the groups of patients with different number of
organs involved in sarcoidosis (Table I).
Statistically significant correlation was obtained
with the analysis, between the SUV representing sar-
coidosis focal granulomatous activity detected on 18F-
FDG PET/CT examination and serum chitotriosidase
levels (Figure 5). Serum ACE levels showed no corre-
lation with 18F-FDG PET/CT detected sarcoidosis
activity (r=-0.102, P=0.459).
Analyzing sarcoidosis duration, significant neg-
ative correlation with the levels of chitotriosidase was
found suggesting that longer disease duration corre-
lated with lower serum levels of chitotriosidase (r=-
0.205, P<0.0001). No significant correlation was
estimated between sarcoidosis duration and serum
ACE activity (r=-0.076, P=0.1155) (Figure 6).
Discussion
The aims of this study were to evaluate the sensi-
tivity and specificity of chitotriosidase in assessment of
sarcoidosis activity in a population of 430 sarcoidosis
patients, and to correlate it with other markers of disease
activity, i.e. radiographic features, number of or gans
involved, disease duration and for the first time PET/CT
findings, as well as to compare it with serum ACE. To
our knowledge, this is the largest study done to eval-
uate the activity of serum chitotriosidase in a sar-
coidosis population and healthy controls, comparing
it with serum ACE levels.
The study has confirmed the findings of Grosso
et al. (15) that individuals with sarcoidosis have high-
er serum chitotriosidase levels than healthy controls.
Similar findings were noted in the study of Bargagli et
al. (28) on 232 sarcoidosis patients, where serum chi-
totriosidase concentrations were significantly higher
in patients than in healthy controls and were directly
correlated with ACE levels (28). 
However, we found serum ACE levels, the most
frequently used marker of sarcoidosis activity, also sig-
nificantly increased in patients with sarcoidosis. Both
markers showed significantly higher values in the
male patients’ population. The higher serum ACE lev-
els in male adults do not correlate with the previous
findings from the literature, but might confirm the
fact that the reference values for ACE should be
established locally (29, 30). 
Comparing the two biomarkers (serum chito trio -
sidase and ACE levels) of sarcoidosis activity with the
chest X ray findings (radiographic staging of sarcoido-
sis), significant correlation was found between the
serum chitotriosidase levels and stage of the lung dis-
ease, while no correlation between serum ACE levels
and radiographic staging was observed (Figure 4). As
it is believable that the radiographic stage of sarcoido-
sis in general predicts prognosis (31), a positive asso-
ciation between chitotriosidase levels and radiograph-
ic stage suggests that chitotriosidase may be an
important biochemical marker of valuable prognostic
J Med Biochem 2016; 35 (4) 397
Figure 6 Disease duration and S-ACE levels and S-Chitotriosidase levels.
significance. Similar findings were confirmed by sev-
eral other authors (15, 17, 28, 32). Golab et al. (32)
even suggested that because of the correlation with
the radiological stages of disease, the determination
of chitotriosidase activity might decrease the number
of X-ray examinations.
Considering the peak value of serum chitotriosi-
dase and the stage of the lung disease, results from
this study differ from the study of Bargagli et al. (17),
who found the highest serum chitotriosidase levels in
stage 3 of the lung disease. Our data showed the
highest serum chitotriosidase values in the stage 2 of
the lung disease. This only adds to the still open ques-
tion: is chitotriosidase the enzyme that induces the
over-expression of profibrotic type-2 (Th2) cytokines,
the observation which is more in tune with stage 3 of
the lung disease, or does it express the activity of the
»fresh« granuloma, which is still identifiable in the
stage 2 of the lung disease. Analyzing the disease
duration, we found significant correlation between
serum chitotriosidase levels and sarcoidosis duration.
The correlation was negative (Figure 6); the longer
the duration, the lower the serum chitotriosidase lev-
els in sarcoidosis. This finding also reflects the fact
that in patients with long lasting sarcoidosis, thus evi-
dently the chronic form, the activity of the granuloma-
tous inflammation is very low or even suppressed.
These are patients on long lasting immunosuppres-
sive therapy regimes, or at least on morbostatic doses.
Unfortunately, chitotriosidase deficiency and carrier
frequency occur in 6% and 30–40% of the general
population, respectively, due to mutations (33). 
Interpretation of plasma chitotriosidase levels is
complicated due to the occurrence of the 24 bp dupli-
cation in the chitotriosidase gene, which results in an
inactive protein in 5–6% of the general population. The
carrier prevalence is as high as 30–40% and chitotrio -
sidase activity is half of that in individuals with the wild-
type gene (33). The most important difference was
noticed between the two potential serum markers (ACE
and chitotriosidase) considering sarcoidosis acivity. Our
study revealed a high sensi tivity of 82.5% for serum
levels of chitotriosidase of only 100 nmol/mL/h to
confirm active sarcoidosis, and specificity of 70.0% to
exclude sarcoidosis activity (Figure 3). (Cut off of 32.0
U/L for serum levels of ACE had the sensitivity of
66.0% and the specificity of 54%.) Similarly, in the
study of Bargagli et al. (28) on 232 sarcoidosis
patients, ROC curve analysis for chitotriosidase
revealed 88.6% sensitivity and 92.8% specificity.
The comparison of 18F-FDG PET/CT findings
with the two markers of disease activity, done in a sub-
group of 55 patients from the analyzed cohort,
revealed most strongly the positive correlation
between sarcoidosis activity and serum chitotriosidase
levels. This is a unique finding of this study.
Inflammatory lesions are metabolically active, and
they can change quickly, growing in a short interval of
time, and disagreement with the chest X ray may
occur; besides the whole body 18F-FDG-PET illumi-
nates the total granulomatous inflammation in indi-
viduals with already proven sarcoidosis (Figure 5).
Patients with uncontrolled sarcoidosis (active
persistent disease) despite the therapy had very high
serum chitotriosidase levels, a finding which is in line
with Bargagli et al. (28). Speaking in the words of a
recently published new phenotype classification for
patients with sarcoidosis (COS) by R Baughman et al.
(23), these are patients with persistent disease on
steroids and with functional deterioration within the
last year. In our study, serum chitotriosidase levels sig-
nificantly correlated with COS categories; however,
the correlation between COS categories and serum
ACE levels was not significant. In the study of Bargagli
et al. (28) on 232 sarcoidosis patients, the lowest
activities of chitotriosidase were found in untreated
patients in remission (COS-1), while the highest
enzyme activities were found in symptomatic patients
with persistent disease on steroids and with function-
al deterioration in the last year (COS-9). Boot et al.
(4) have noted that the increase in plasma chitotrio -
sidase correlated with the stage of disease, being
highest in active sarcoidosis with extrapulmonary in -
volvement. Therapy with steroids resulted in clear re -
 duction of plasma chitotriosidase and relapse of dis-
ease activity was preceded by increase in this
parameter. The correlations of chitotriosidase activity
and duration of sarcoidosis may be even stronger if
we took chitotriosidase genotype status into account;
however, we did not perform chitotriosidase genotyp-
ing, which is a limitation of this study (34, 35). A lim-
itation of the study at first glance might also be that
we did not analyze our patient group considering the
therapy. As described, the majority of our patients
were on therapy; due to active sarcoidosis (230
patients) or in order to prevent further deterioration of
the chronic persistent disease (46 patients).
Although on therapy, a certain number of
patients experienced symptoms of sarcoidosis activity,
or activity was suggested in clinically asymptomatic
patients, but with unquestionable and marked
roentgenographic deterioration, or with major mani-
festations such as recently developed skin lesions,
parotid or ocular involvement, peripheral lymph -
adenopathy, or deterioration of pulmonary function
tests, suggesting disease activity. So, considering only
the parameters of disease activity distinguishing them
from the treatment, this study succeeded in its major
goal to evaluate the utility of these different markers
for the assessment of activity in sarcoidosis.
Conclusion
In conclusion, this is the largest study done with
the major task to evaluate the significance of serum
chitotriosidase in verifying sarcoidosis activity. The
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study added to the research of other authors in the
field of possible biomarkers of sarcoidosis, validating
the significance of serum chitotriosidase in assessing
not only the activity of sarcoidosis at first glance, but
also in investigating the possible disease chro nicity.
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